Figure 2.

Antigen-specific humoral immunity induced by treatment with recombinant MVA vaccine candidates expressing NiV-G. IFNAR−/− mice were immunized and boosted 21 days later with 10⁸ PFU of MVA–NiVsG or MVA–NiV-G via the intramuscular (i.m.) route (n = 3–7 per group). Mice inoculated with MVA or saline (mock) were used as controls. Sera collected 18 days after the first immunization (Prime) and 10 days (Prime-Boost) after the last immunization were analyzed for NiV-G-specific IgG titers by ELISA. Graphs show the antigen-specific serum IgG titer.